Resource Logo

Estimating the cost-effectiveness of atovaquone versus intravenous pentamidine in the treatment of mild- to moderate-PCP patients.


3rd Conf Retro and Opportun Infect. 1996 Jan 28-Feb 1;:159. Unique

Pneumocystis carinii pneumonia (PCP) is one of the most costly opportunistic infections among persons with AIDS. Over 50 percent of patients develop toxicity to the major anti-PCP medications, trimethoprim-sulfamethoxazole (TMP/SMX) and pentamidine. Atovaquone was recently approved for persons with mild to moderate PCP who are intolerant to TMW/SMX. A decision-tree model was developed to estimate the costs and cost-effectiveness of atoavquone therapy compared to intravenous pentamidine therapy for TMP/SMX intolerant patients with mild to moderate PCP. Clinical outcomes are based on data from a randomized controlled trial comparing the two medications. The economic outcomes are based on treatment algorithms derived from discharge data, published reports, and clinical judgement. The total expected cost of treating a patient with atovaquone is $3,990 compared to $5,665 for pentamidine under the baseline scenario. The decision model provides insights into the large cost-savings associated with treating mild to moderate PCP on an outpatient basis.

Acquired Immunodeficiency Syndrome/COMPLICATIONS Antifungal Agents/*THERAPEUTIC USE Cost of Illness *Cost-Benefit Analysis Human Infusions, Intravenous Naphthoquinones/*THERAPEUTIC USE Pentamidine/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Pneumonia, Pneumocystis carinii/COMPLICATIONS/*PREVENTION & CONTROL ABSTRACT


Information in this article was accurate in November 30, 1996. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.